Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Oslo, Norway.
Department of Acute Medicine, Division of Medicine, Oslo University Hospital Ullevål, Oslo, Norway.
Crit Care Explor. 2024 Jul 16;6(7):e1128. doi: 10.1097/CCE.0000000000001128. eCollection 2024 Jul.
Under normal conditions, pulmonary megakaryocytes are an important source of circulating thrombocytes, causing thrombocyte counts to be higher in arterial than venous blood. In critical COVID-19, thrombocytes may be removed from the circulation by the lungs because of immunothrombosis, possibly causing venous thrombocyte counts to be higher than arterial thrombocyte counts. In the present study, we investigated time-dependent changes in pulmonary turnover of thrombocytes during critical COVID-19 by measuring arteriovenous thrombocyte differences. We hypothesized that the early stages of the disease would be characterized by a net pulmonary removal of circulating thrombocytes because of immunothrombosis and that later stages would be characterized by a net pulmonary release of thrombocytes as normal pulmonary function is restored.
Cohort study with repeated measurements of arterial and central venous thrombocyte counts.
ICU in a large university hospital.
Thirty-one patients with critical COVID-19 that were admitted to the ICU and received invasive or noninvasive mechanical ventilation.
None.
We found a significant positive association between the arteriovenous thrombocyte difference and time since symptom debut. This finding indicates a negative arteriovenous thrombocyte difference and hence pulmonary removal of thrombocytes in the early stages of the disease and a positive arteriovenous thrombocyte difference and hence pulmonary release of thrombocytes in later stages. Most individual arteriovenous thrombocyte differences were smaller than the variance coefficient of the analysis.
The results of this study support our hypothesis that early stages of critical COVID-19 are characterized by pulmonary removal of circulating thrombocytes because of immunothrombosis and that later stages are characterized by the return of normal pulmonary release of thrombocytes. However, in most cases, the arteriovenous thrombocyte difference was too small to say anything about pulmonary thrombocyte removal and release on an individual level.
在正常情况下,肺巨核细胞是循环血小板的重要来源,导致动脉血中的血小板计数高于静脉血。在严重的 COVID-19 中,由于免疫血栓形成,血小板可能会从循环中被肺部清除,这可能导致静脉血小板计数高于动脉血小板计数。在本研究中,我们通过测量动静脉血小板差异来研究严重 COVID-19 期间血小板在肺部的周转率随时间的变化。我们假设疾病的早期阶段由于免疫血栓形成,会出现循环血小板从肺部净清除的特征,而后期阶段则会出现随着正常肺功能的恢复,血小板从肺部净释放的特征。
队列研究,重复测量动脉和中心静脉血小板计数。
一家大型大学医院的 ICU。
31 名因严重 COVID-19 而入住 ICU 并接受有创或无创机械通气的患者。
无。
我们发现动静脉血小板差异与自症状出现以来的时间之间存在显著正相关。这一发现表明早期疾病阶段的动静脉血小板差异为负,即血小板从肺部清除,而后期阶段的动静脉血小板差异为正,即血小板从肺部释放。大多数个体动静脉血小板差异都小于分析的变异系数。
这项研究的结果支持我们的假设,即严重 COVID-19 的早期阶段以免疫血栓形成导致的循环血小板从肺部清除为特征,而后期阶段则以正常肺释放血小板的恢复为特征。然而,在大多数情况下,动静脉血小板差异太小,无法在个体水平上说明肺部血小板的清除和释放。